Hence, it is conceivable that, by increasing cardio-parasympathetic activity, intranasal oxytocin might hold promise to prevent transition into full-blown psychosis and/or relapse and address potential cardiovascular comorbidities2 in patients with psychosis or at risk. Here, OXT is linked to psychotic disorder.